Changes In Lipid Profile Research Articles

Yolk free egg substitute improves the serum phospholipid profile of mice with metabolic syndrome based on lipidomic analysis

In this study, the impacts of egg consumption on mice model of metabolic syndrome (MetS) were comparatively investigated. Mice were divided into five groups (n=8): normal diet group (ND), high-fat diet group (HFD), HFD with whole egg group (WE), HFD with free-yolk egg substitute group (YFES), and HFD with lovastatin group (Lov). Main biochemical indexes and a non-targeted lipidomic analysis were employed to insight the lipid profile changes in serum. It was revealed that WE could significantly improve serum biochemical indexes by reducing body weight, low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC), while increasing high-density lipoprotein cholesterol. YFES exhibited remarkably better performance in increasing phosphatidylglycerol and phosphatidic acids, while decreasing phosphatidylinositol than WE. A total of 50 differential lipids biomarkers tightly related to glycerophospholipids metabolism were screened out. Carnitine C18:2 and C12:1, SM (d18:0/12:0), and SM (d18:1/14:1) were significantly upregulated in YFES compared to WE. YFES reduced expression of SREBP-1c and Cpt1a, while did not affect the expression of PPAR-α. Sphingomyelin biomarkers were positively related to the TC (|r| > 0.6), while PPAR-α was negatively correlated with triglyceride and LDL-C levels. To sum up, YFES attenuated HFD-induced MetS by improving the serum phospholipids, which account for its modulation of glycerophospholipid metabolism.

The hormonal status and the possibility of predicting outcomes in patients with different types of chronic disorders of consciousness

BACKGROUND: Chronic disorders of consciousness are rare clinical conditions that develop after coma and are accompanied by the restoration of wakefulness without the full restoration of consciousness 28 days or longer after brain damage. All women with chronic disorders of consciousness have menstrual irregularities such as oligomenorrhea or secondary amenorrhea. Clinical experience shows that recovery of the menstrual response in a number of patients with chronic disorders of consciousness precedes or is combined with recovery of clear consciousness. The results of a comprehensive examination of patients with different types of ovarian failure, depending on the type of chronic disorders of consciousness, have not been presented in the literature. Therefore, an analysis of the results of such an examination can become the basis for the selection of pathogenetically substantiated hormone-modulating therapy and the development of predictive models for assessing recovery of consciousness from chronic disorders of consciousness.
 AIM: The aim of this study was to assess the variants of ovarian failure in patients with different types of chronic disorders of consciousness and to develop prognostic models that evaluate the possibility of restoring consciousness.
 MATERIALS AND METHODS: This study enrolled 30 patients aged 18 to 44 years divided into three groups depending on the level of consciousness: vegetative state / unresponsive wakefulness syndrome (n = 12), minimally conscious state minus (n = 6), and minimally conscious state plus (n = 12). Here we examined lipid profile changes (total cholesterol, low-density lipoprotein, high-density lipoprotein) and levels of follicle-stimulating hormone, luteinizing hormone, prolactin, total testosterone, estradiol, free triiodothyronine, thyroxine, thyroid-stimulating hormone, adrenocorticotropic hormone, cortisol, and vitamin 25(OH)D in the blood, as well as levels of melatonin in the blood serum and 6-sulfatoxymelatonin in the urine. In addition, in the blood serum and cerebrospinal fluid, we evaluated levels of brain-derived neurotrophic factor, apoptosis antigen 1, Fas-ligand, glutamate, and S100 protein. We also performed ultrasound of the pelvic organs and mammary glands, magnetic resonance imaging of the chiasmal-sellar region, cervical screening, and genetic study (the prothrombin gene mutation and the Leiden factor).
 RESULTS: Hypogonadotropic and normogonadotropic ovarian failures were detected in 36.7% and 63.3% of patients, respectively. No differences in neurotrophin levels between the study groups were found. Three mathematical models were formulated for predicting the recovery of patients into a clear consciousness using the levels of thyroid-stimulating hormone, prolactin, follicle-stimulating hormone, anti-Mllerian hormone, total testosterone, and the age of patients.
 CONCLUSIONS: The presented prognostic models by determining hormone levels in the blood plasma allow for calculating the output of patients in clear consciousness. Further research and accumulation of data on patients with chronic disorders of consciousness are promising for the development of new effective approaches to the rehabilitation of this group of patients.

Effect of Cocoa Beverage and Dark Chocolate Intake on Lipid Profile in People Living with Normal and Elevated LDL Cholesterol: A Systematic Review and Meta-Analysis

Cocoa beverage and dark chocolate are important dietary sources of polyphenol and have been hypothesised to improve the lipid profile. This systematic review and meta-analysis aimed to investigate the effect of cocoa beverage and dark chocolate intake on lipid profile in individuals living with normal and elevated LDL cholesterol. The question on whether cocoa beverage and chocolate differentially modify the lipid profile was also explored. A systematic literature search was conducted on PubMed and Cochrane Library on 26 February 2022 following the PRISMA guideline. Cocoa beverage and chocolate consumption had no significant effect on circulating concentrations of total cholesterol, LDL cholesterol, and triglycerides (p > 0.05, all), but favourably and significantly increased circulating concentration of HDL cholesterol by 0.05 (95% CI [0.02, 0.09]) mmol/L (p = 0.002). Changes in lipid profile were similar when comparing populations with normal vs. elevated LDL cholesterol (p > 0.05, all). When considering the food matrix, cocoa beverage intake significantly increased HDL cholesterol by 0.11 (95% CI [0.06, 0.17]) mmol/L (p < 0.001), but the improvement in HDL cholesterol was not significant when chocolate (p = 0.10) or a combination of cocoa beverage and chocolate (p = 0.19) (subgroup differences, p = 0.03) was administered. Cocoa consumption could be recommended as part of a healthy diet in the general population with normal and elevated LDL cholesterol.

PKA regulatory subunit Bcy1 couples growth, lipid metabolism, and fermentation during anaerobic xylose growth in Saccharomyces cerevisiae.

Organisms have evolved elaborate physiological pathways that regulate growth, proliferation, metabolism, and stress response. These pathways must be properly coordinated to elicit the appropriate response to an ever-changing environment. While individual pathways have been well studied in a variety of model systems, there remains much to uncover about how pathways are integrated to produce systemic changes in a cell, especially in dynamic conditions. We previously showed that deletion of Protein Kinase A (PKA) regulatory subunit BCY1 can decouple growth and metabolism in Saccharomyces cerevisiae engineered for anaerobic xylose fermentation, allowing for robust fermentation in the absence of division. This provides an opportunity to understand how PKA signaling normally coordinates these processes. Here, we integrated transcriptomic, lipidomic, and phospho-proteomic responses upon a glucose to xylose shift across a series of strains with different genetic mutations promoting either coupled or decoupled xylose-dependent growth and metabolism. Together, results suggested that defects in lipid homeostasis limit growth in the bcy1Δ strain despite robust metabolism. To further understand this mechanism, we performed adaptive laboratory evolutions to re-evolve coupled growth and metabolism in the bcy1Δ parental strain. The evolved strain harbored mutations in PKA subunit TPK1 and lipid regulator OPI1, among other genes, and evolved changes in lipid profiles and gene expression. Deletion of the evolved opi1 gene partially reverted the strain's phenotype to the bcy1Δ parent, with reduced growth and robust xylose fermentation. We suggest several models for how cells coordinate growth, metabolism, and other responses in budding yeast and how restructuring these processes enables anaerobic xylose utilization.

Antimalarial and Antioxidant Activities of Ethanolic Stem Bark Extract of Terminalia macroptera in Swiss Albino Mice Infected with Plasmodium berghei.

Reduction of oxidative stress during malaria infection is considered as being of great benefit so long as treatment and drug development approaches are concerned. This study had the aim of evaluating the antimalarial and antioxidant activities of the ethanolic extract of Terminalia macroptera in Swiss albino mice infected with the Plasmodium berghei NK65 strain. In vivo, the antiplasmodial activity of the plant ethanolic extract was tested in a four-day suppressive and curative assay using P. berghei in Swiss albino mice. The extract was administered to the mice at doses of 125, 250, and 500 mg/kg per day. Then, parameters, such as parasite suppression and survival time of the mice, were evaluated. Furthermore, the effect of plant extract on liver damage, oxidative stress indicators, and lipid profile changes in P. berghei-infected mice were studied. Administration of T. macroptera significantly suppressed P. berghei infection by 55.17%, 70.69%, and 71.10% at doses of 125, 250, and 500 mg/kg, respectively, whereas chloroquine had 84.64% suppression relative to the untreated group 1% Dimethyl sulfoxide (1% DMSO) at day 4 (post-infection) in the four-day suppressive test. This suppression activity rate was dose-dependent. The curative test also presented a significant reduction in parasitemia and an extension of the survival time of the treated groups. Treatment of infected parasitized mice with the extract of T. macroptera had a significant (p < 0.05) reduction in parameters, such as total protein, aspartate aminotransferase, and alanine aminotransferase. Infection may also lead to a significant increase in the enzymatic activity of liver catalase and superoxide dismutase compared with the normal control group. The non-enzymatic antioxidant activity in parasitized mice was significantly reduced in malondialdehyde and increased in glutathione and nitric oxide when compared with the normal control group. These findings support the ethnobotanical use of T. macroptera stem bark as an antimalarial remedy coupled with antioxidant activity. However, further in vivo toxicity tests are required to ascertain its safety.

Primary care blood tests show lipid profile changes in pre-symptomatic amyotrophic lateral sclerosis.

Multiple sources of evidence suggest that changes in metabolism may precede the onset of motor symptoms in amyotrophic lateral sclerosis. This study aimed to seek evidence for alterations in the levels of blood indices collected routinely in the primary care setting prior to the onset of motor symptoms in amyotrophic lateral sclerosis. Premorbid data, measured as part of routine health screening, for total cholesterol, high-density and low-density lipoprotein cholesterol, triglyceride, glycated haemoglobin A1c and creatinine were collected retrospectively from (i) a cohort of amyotrophic lateral sclerosis patients attending a specialist clinic (n = 143) and (ii) from primary care-linked data within UK Biobank. Data were fitted using linear mixed effects models with linear b-splines to identify inflection points, controlling for age and sex. In specialist amyotrophic lateral sclerosis clinic cases, models indicated decreasing levels of total and low-density lipoprotein cholesterol prior to an inflection point in the years before symptom onset (total cholesterol 3.25 years, low-density lipoprotein cholesterol 1.25 years), after which they stabilized or rose. A similar pattern was observed in amyotrophic lateral sclerosis cases within UK Biobank, occurring several years prior to diagnosis (total cholesterol 7 years, low-density lipoprotein cholesterol 7.25 years), differing significantly from matched controls. High-density lipoprotein cholesterol followed a similar pattern but was less robust to sensitivity analyses. Levels of triglyceride remained stable throughout. Glycated haemoglobin temporal profiles were not consistent between the clinic and biobank cohorts. Creatinine level trajectories prior to amyotrophic lateral sclerosis did not differ significantly from controls but decreased significantly in the symptomatic period after an inflection point of 0.25 years after symptom onset (clinic cohort) or 0.5 years before diagnosis (UK Biobank). These data provide further evidence for a pre-symptomatic period of dynamic metabolic change in amyotrophic lateral sclerosis, consistently associated with alterations in blood cholesterols. Such changes may ultimately contribute to biomarkers applicable to population screening and for pathways guiding the targeting of preventative therapy.

Real-World Effectiveness and Safety of Hydrogen Inhalation in Chinese Patients with Type 2 Diabetes: A Single-Arm, Retrospective Study.

To evaluate the real-life effectiveness and safety of Chinese patients with type 2 diabetes mellitus (T2DM) receiving hydrogen inhalation (HI) treatment as a supplementary treatment. This retrospective, multicenter, observational 6-months clinical study included T2DM patients maintaining HI, visited at 4 time points. The primary outcome is the mean change in glycated hemoglobin (HbA1c) at the end of the study compared to baseline. The secondary outcome is analyzing the mean change of fasting plasma glucose (FPG), weight, lipid profile, insulin dose and homeostasis model assessment. Linear regression and logistics regression are applied to evaluate the effect of HI after the treatment. Of the 431 patients comprised, it is observed a significant decrease in HbA1c level (9.04±0.82% at baseline to 8.30±0.99% and 8.00±0.80% at the end, p<0.001), FPG (165.6±40.2 mg/dL at baseline to 157.1±36.3mg/dL and 143.6±32.3mg/dL at the end, p<0.001), weight (74.7±7.1kg at baseline to 74.8±10.0kg and 73.6±8.1kg at the end, p<0.001), insulin dose (49.3±10.8U/d at baseline to 46.7±8.0U/d and 45.2±8.7U/d, p<0.001). The individuals in subgroup with higher baseline HbA1c and longer daily HI time duration gain greater HbA1c decrease after 6 months. Linear regression shows that higher baseline HbA1c level and shorter diabetes duration are significantly in relation to greater HbA1c reduction. Logistics regression reveals that lower weight is associated with a higher possibility of reaching HbA1c<7%. The most common adverse event is hypoglycemia. HI therapy significantly improves glycemic control, weight, insulin dose, lipid metabolism, β-cell function and insulin resistance of patients with type 2 diabetes after 6 months. Higher baseline HbA1c level and shorter diabetes duration is related to greater clinical response to HI.

Protective Effect of Baclofen on Ovarian Cystogenesis and Morphine-Induced Lipid Profile Change in Female Rats.

Morphine induces ovarian cysts that cause obesity and disrupt sex hormone secretion. Baclofen, a gamma-aminobutyric acid receptor agonist, can help regulate sex hormones and reduce harmful blood lipids by protecting against morphine-induced gamma-aminobutyric acid inhibition. We investigated the prophylactic effect of baclofen in rats receiving morphine by comparing with the untreated groups. Forty eight female Wistar rats were randomly divided into several groups, including control (saline 1 mL/kg, i.p.), morphine (5 mg/kg, i.p.), baclofen (10, 20, and 30 mg/kg, i.p.), and baclofen (10, 20, and 30 mg/kg) before morphine (5 mg/kg). Twenty four hours after the treatment, blood and serum samples were taken to check the levels of gonadotropins (LH & FSH) and lipid profile. The ovaries and uterus were also studied, and a proinflammatory nitric oxide (NO) diagnostic test was completed. The results were analyzed using analysis of variance (α = 0.05). In comparison with the control group, the levels of LH and not FSH decreased in the morphine group and the number of ovarian cysts was more in the morphine group. These problems were not observed in the group of baclofen alone and baclofen + morphine. However, the triglyceride level increased slightly in the baclofen 30 mg/kg + morphine group. But the LDL level somewhat decreased. The proinflammatory NO system did not show significant activation in the ovary and uterus, except for the baclofen 10 mg/kg + baclofen group. Morphine can cause ovarian cysts by lowering LH but baclofen prophylaxis can protect reproductive properties by adapting major metabolic changes.

Evaluation of phytochemicals from Morinda citrifolia (Noni) fruit extracts against nicotine-induced different physiological functions: An experimental study on albino rat model

Background: People are consuming nicotine in the form of cigars, pipes and, cigarettes etc. and they are suffering from lungs, liver, heart diseases, involving hidden killer for human health. The Morinda citrifolia (Noni) is an important medicinal plant of the Rubiaceae family, commonly known as Ach, Bartundi, Hurdi and Sarangi in Bengali. Traditionally it is used in various purposes of food and medicines.Aims and objectives: The present study was undertaken to highlight and find out the different phytochemicals from noni fruit extractand its role against nicotine-induced cardiac damage, mainly serum lipid profile and hematological changes and development of biobased anti-nicotinic agent is now become an active research goal.Materials and methods: Fruits of the selected plant was collected and prepared methanolic fruit extract. Fruit of M. citrifolia (Noni)contains several nutrients and phytochemicals. GC-MS analyzed the methanolic fruit extract of M. citrifolia to determine chemicalconstituents. The noni fruit extract was applied against the rat model’s nicotine-induced blood parameters.Results and discussion: Hematological and Biochemical alteration of cardiovascular experiments was done in albino rat. This studyrevealed that the fruits extract of M. citrifolia may be capable of reducing the cholesterol and hemoglobin levels significantly (p&lt;0.05)in blood after nicotine treatment in rat models.Conclusion: So, we try to find out the role of active principles and phytochemicals from this plant to combat the nicotinic activity.Results show that Noni fruit methanolic extract may have some protective effects against nicotine and its action.

Effect of Transoral Outlet Reduction on Hepatic Fibrosis in Roux-en-Y Gastric Bypass Patients with Weight Regain and Non-alcoholic Fatty Liver Disease.

Weight regain after Roux-en-Y gastric bypass (RYGB) is associated with worsening of liver outcomes. However, the effect of transoral outlet reduction (TORe) on liver fibrosis in RYGB patients with weight regain and possible advanced fibrosis remains unknown. This was a retrospective analysis of prospectively collected data of RYGB patients who underwent TORe for weight regain. Only patients with possible advanced fibrosis were included. TORe was performed using either an endoscopic suturing device (S-TORe) or plication device (P-TORe) to reduce the gastrojejunal anastomosis (GJA) and pouch sizes. Primary outcomes included changes in non-invasive tests (NITs) for fibrosis at 6-12months. Secondary outcomes included weight loss and changes in insulin resistance and lipid profile at 6-12months. Fifty RYGB patients were included. Baseline age and BMI were 55 ± 11years and 40.1 ± 7.3kg/m2. Baseline GJA and pouch sizes were 20 ± 7mm and 5 ± 2cm, respectively. Thirty patients (60%) underwent S-TORe and 20 patients (40%) underwent P-TORe. At 12months following TORe, there were statistically significant improvements in NITs for fibrosis, including ALT, AST and FIB-4. There was a trend towards significant improvement in liver stiffness measurement on transient elastography. Patients experienced 8.8 ± 11.2% total weight loss (TWL) (p < 0.0001), with 60% experiencing at least 10% TWL. Additionally, there was a significant improvement in HbA1c and a trend toward significant improvement in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), suggestive of improved insulin sensitivity. TORe is associated with an improvement in hepatic fibrosis in patients with NAFLD and possible advanced fibrosis.

Refueling the post COVID-19 brain: potential role of ketogenic medium chain triglyceride supplementation: an hypothesis.

COVID-19 infection causes cognitive changes in the acute phase, but also after apparent recovery. Over fifty post (long)-COVID symptoms are described, including cognitive dysfunction ("brain fog") precluding return to pre-COVID level of function, with rates twice as high in females. Additionally, the predominant demographic affected by these symptoms is younger and still in the workforce. Lack of ability to work, even for six months, has significant socio-economic consequences. This cognitive dysfunction is associated with impaired cerebral glucose metabolism, assessed using 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET), showing brain regions that are abnormal compared to age and sex matched controls. In other cognitive conditions such as Alzheimer's disease (AD), typical patterns of cerebral glucose hypometabolism, frontal hypometabolism and cerebellar hypermetabolism are common. Similar FDG-PET changes have also been observed in post-COVID-19, raising the possibility of a similar etiology. Ketone bodies (B-hydroxybutyrate, acetoacetate and acetone) are produced endogenously with very low carbohydrate intake or fasting. They improve brain energy metabolism in the face of cerebral glucose hypometabolism in other conditions [mild cognitive impairment (MCI) and AD]. Long-term low carbohydrate intake or prolonged fasting is not usually feasible. Medium chain triglyceride (MCT) is an exogenous route to nutritional ketosis. Research has supported their efficacy in managing intractable seizures, and cognitive impairment in MCI and AD. We hypothesize that cerebral glucose hypometabolism associated with post COVID-19 infection can be mitigated with MCT supplementation, with the prediction that cognitive function would also improve. Although there is some suggestion that post COVID-19 cognitive symptoms may diminish over time, in many individuals this may take more than six months. If MCT supplementation is able to speed the cognitive recovery, this will impact importantly on quality of life. MCT is readily available and, compared to pharmaceutical interventions, is cost-effective. Research shows general tolerability with dose titration. MCT is a component of enteral and parenteral nutrition supplements, including in pediatrics, so has a long record of safety in vulnerable populations. It is not associated with weight gain or adverse changes in lipid profiles. This hypothesis serves to encourage the development of clinical trials evaluating the impact of MCT supplementation on the duration and severity of post COVID-19 cognitive symptoms.

The role of Elateriospermum tapos yoghurt in mitigating high-fat dietary cause of maternal obesity-an experimental study.

Maternal obesity is the key predictor for childhood obesity and neurodevelopmental delay in the offspring. Medicinal plants are considered to be the safe and best option, and at the same time, probiotic consumption during pregnancy provides beneficial effects for both the mother and the child. Current research has shown that Elateriospermum tapos (E. tapos) yoghurt is safe to consume and consists of many bioactive compounds that can exert an anti-obesity effect. Thus, this study has been designed to study the role of E. tapos yoghurt in mitigating maternal obesity. In this study, a total of 48 female Sprague Dawley (SD) rats were assigned to six groups, with eight rats per group, and obesity was induced over 16 weeks with a high-fat diet (HFD) pellet. On the 17th week, the rats were allowed to mate and pregnancy was confirmed through vaginal smear. The obese induced group was further divided into negative and positive control groups, followed by E. tapos yoghurt treatment groups with three different concentrations (5, 50, and 500 mg/kg). The changes in body weight, calorie intake, lipid profile, liver profile, renal profile, and histopathological analysis were measured on postnatal day (PND) 21. The results show that the group with the highest concentration of E. tapos yoghurt (HYT500) supplementation shows gradual reduction in body weight and calorie intake on PND 21 and modulates the lipid level, liver, and renal enzymes to a normal level similar to the normal group. In histological analysis, HYT500 reverses the damage caused by HFD in liver and colon, and reverses the adipocytes' hypertrophy in retroperitoneal white adipose tissue and visceral fat. In conclusion, supplementation of E. tapos yoghurt during the gestational period up to weaning is effective in the gradual weight loss of maternal obese dams from the 500-mg/kg-supplemented group in this study.

Lipid profile changes associated with antiretroviral therapies in a real-world cohort

ObjectiveTo compare lipid profile changes and cardiovascular events among HIV naïve and experienced patients from a real-world cohort treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate or dolutegravir/abacavir/lamivudine. MethodA retrospective cohort study in HIV naïve and experienced people at a reference hospital in Spain was done. During the follow-up (March 2015–June 2019), patients were treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate or dolutegravir/abacavir/lamivudine. Epidemiological, clinical, and immunovirological variables were recorded. A statistical analysis of the lipid profile at baseline, 48, and 120 weeks after initiating the study therapy, cardiovascular events (myocardial infarction, heart failure, cerebrovascular accident, deep venous thrombosis, myocardiopathy, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction), and cardiovascular risks factors was performed. Data were analysed in naïve and experienced patients from each of the study treatments. The data were obtained from the medical history. The statistical analysis was performed with SPSS v. 24 software. ResultsA total of 266 and 191 patients receiving treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine were included in the study, respectively. After 120 weeks of treatment, a worsening of the lipid profile was found in the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate group, both in naïve and experienced patients, whereas not so conspicuously observed in the dolutegravir/abacavir/lamivudine group. Statistically significant differences between both groups were found in experienced patients favouring dolutegravir/abacavir/lamivudine; in total cholesterol (204.1±38.2 vs. 187.3±29.4, P < .001) and LDL-C (126.1±31.9 vs. 113.5±28.5, P = .001) at week 48, and in total cholesterol (201.1±33.4 vs. 188.7±33.9, P = .013) and HDL-C (54.2±15.6 vs. 48.3±14.3, P = .01) at week 120. No significant differences in cardiovascular events were found, neither in naïve nor in experienced patients. ConclusionsThe lipid profile among elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate group worsened throughout the follow-up, both in naïve and experienced patients, not so remarkable in the dolutegravir/abacavir/lamivudine group. Both regimens were well tolerated, with similar rates of cardiovascular events.

369-OR: Continued Weight Loss with Semaglutide Once-Weekly in Patients without Type 2 Diabetes and Postbariatric Treatment Failure

Purpose: Recently, we published promising retrospective 6-months follow-up data on the effectiveness of semaglutide 0.5mg once-weekly in patients with weight regain (WR) or insufficient weight loss (IWL) following bariatric metabolic surgery (BS). Therefore, we aimed to investigate whether weight loss was sustained over a 12-months period with semaglutide in patients without type 2 diabetes (T2D) with WR or IWL. Materials and Methods: Postbariatric patients without T2D with WR or IWL (n=29) were included in the analysis. The primary endpoint was weight loss 12 months after initiation of adjunct treatment. Secondary endpoints included change in BMI, HbA1c, lipid profile, hs-CRP and liver enzymes. Results: Total weight loss during semaglutide treatment added up to 14.7±8.9% (mean±SD, p&amp;lt;0.001) after 12 months. Categorical weight loss was &amp;gt;5% in 89.7% of patients, &amp;gt;10% in 62.1% of patients, &amp;gt;15% in 34.5% of patients, &amp;gt;20% in 24.1% of patients and &amp;gt;25% in 17.2% of patients. Among patients with prediabetes at baseline (n=6), 12-months treatment led to normoglycemia in all patients (p&amp;lt;0.05). Conclusion: Treatment options to manage postbariatric treatment failure are scarce, weight loss medications are not approved for use in the postbariatric patient population. Our results imply a clear benefit of adjunct treatment with semaglutide in postbariatric patients. Disclosure A.Lautenbach: Other Relationship; Novo Nordisk, Lilly. J.Wagner: None. F.D.Stoll: None. J.Aberle: Advisory Panel; Novo Nordisk, Speaker's Bureau; Novo Nordisk.

Isotretinoin's Impact on Liver Enzymes and Lipid profile in Acne Patients

Background: Acne is a multifactorial skin lesion and a persistent inflammatory disorder of the pilosebaceous units. One of the most common skin problems, acne vulgaris, which predominantly affects teenagers but can affect anyone at any age, is treated by dermatologists. Objective: The goal of the current study was to assess the profile of changes in ALT, AST, and lipid profiles (TGs, LDL, and HDL) in these patients. Methodology: This cross-sectional study was conducted at tertiary care hospital Dhaka District from June 2020 to July 2022 in the Department of Dermatology. A total of 200 patients were participate in the study. Patients aged more than 15 years, both male and female and patients with diagnosed acne were included in the study. Severely ill patients and not willing to participate were excluded from the study. Data collection was done after approval of protocol using a semi-structured questionnaire through face to face interview. Data were analyzed using a computer programme SPSS 25.0 version. Result: The mean age of male was 22 (±6.7) while in case of female was 24 (±4.5). Minimum age of the patients was 18 year and maximum was 45 year. 75% of the respondents were female and 25% were male. The mean ((±SD)) RBC was 4.9 (0.5)×106 /mL, WBC was 8.4 (3.5)×103 /mL and Hb was 14.3 (1.7)×106 /mL, in case of female the Hb was 12.6 [1.5]× 106 /mL and 14.9 (1.1)×106 /mL for male. In this present study, we discovered that individuals who received isotretinoin medication was statistically significant increases in both TG and LDL levels. Additionally, we discovered statistically significant decreases in HDL levels. In our study, patients who received isotretinoin treatment had liver enzymes that were less altered than lipids. The clinical classification was unaffected, although there were statistically significant increases in AST levels. ALT levels raised as well, but the variations were not statistically significant. Conclusion: Although severe laboratory alterations

Atherogenic Index of Plasma and Oxidized-LDL as Strong and Independent Predictor of CHD in Young Smokers

Cigarette smoking is an environmental risk factor for cardiovascular disease and induces changes in lipid profile by the oxidation of lipids, particularly LDL. Hence the need for determine ox-LDL and its association with atherogenic indices in the prediction of cardiovascular risk arises. The study aimed to determine oxidized-LDL and atherogenic indices in relation to smoking habits in cigarette smokers. This case-control study included 240 individuals in which cigarette smokers were (n=120) and were compared with (n=120) non-smokers. The ox-LDL, APO-A1 and APO-B were performed using Enzyme-linked Immune Sorbent Assay (ELISA) and atherogenic risk ratios were calculated. The study shows that ox-LDL was significantly increased in smokers and significant increase in TC, TGL and LDL was also observed. When compared to nonsmokers, smokers had considerably higher atherogenic risk indices. Pearson correlation tests revealed that ox-LDL and AIP were substantially and positively linked with non-HDL, CRI- Castelli's risk index-I, CRII- Castelli's risk index-II, AC-Atherogenic coefficient, CI-Cholindex and APO-B- Apolipoprotein B (p&lt;0.001). The unadjusted odds ratios for ox-LDL and AIP in the univariate logistic regression analysis were 1.861 (95% confidence interval: 1.347-2.375), p&lt;0.001 and 1.782 (95% confidence interval: 1.490-2.131), P.001) respectively. Multivariate logistic regression analysis demonstrated that ox-LDL and AIP were independent risk factors for CHD in young smokers. In smokers, ox-LDL and atherogenic indices appear to be strong predictors of CHD than conventional lipid parameters.

Efficacy of Different Statins Among Newly Diagnosed Dyslipidemic Patients in Dhulikhel Hospital

Background and Aims: Cardiovascular Disease is the leading cause of death. Prevention of cardiovascular disease is the major aim of treatment of anyone who has risk. Dyslipidemia lies in the center of cardiovascular disease risk. Not only there is difference in pattern of dyslipidemia and response to statins in different ethnic groups, there is difference in mortality due to cardiovascular disease in different race and ethnic group. Atorvastatin and Rosuvastatin are the first line statins. This study is carried out to see how our population responds to these statins in terms of change in lipid profile.&#x0D; Methods: It is a real world observational study. Dyslipidemia patients requiring statins were given either Atorvastatin 10 mg or Rosuvastatin 5 mg according to physician’s discretion. Demographic profile and baseline lipid was recorded. Lipid profile was again recorded after 3 to 4 months of treatment.&#x0D; Result: Out of 343 enrolled only 304 data was analyzed. Total cholesterol decreased by 21.9 % (p = 0.002) in Atorvastatin group and by 22.9 % (p= 0.002) in Rosuvastatin group. Low Density Lipoprotein (LDL) decreased by 22.3 % (p = 0.004) in Atorvastatin group and 21.5% (p=0.005) in Rosuvastatin group. There was no significant difference between two groups.&#x0D; Conclusion: Both Atorvastatin 10 mg and Rosuvastatin 5 mg can reduce the lipids significantly in our population. There is no difference in using Atorvastatin 10 mg or Rosuvastatin 5 mg. However, reduction was only mild to moderate with the given doses.

The Effect of Crackers Enriched with Camelina Sativa Oil on Omega-3 Serum Fatty Acid Composition in Older Adults: A Randomized Placebo-Controlled Pilot Trial

BackgroundCamelina sativa oil is one of the richest dietary sources of omega-3, with polyunsaturated fatty acids amounts of over 50%, linolenic acid content of around 40–45%, and linoleic acid of about 15%. Moreover, this oil is a valuable source of antioxidants which provide oxidative stability. All those features raise interest in considering Camelina oil as an alternative and sustainable oil source providing stable omega-3-rich emulsions for functional food production.ObjectivesThe present study aimed to investigate the effects of Camelina oil-enriched crackers on serum omega-3 concentration, inflammatory markers and serum lipid profile.DesignRandomized placebo-controlled pilot trial. Setting: Research and Development Center (Complife Italia s.r.l.).ParticipantsSixty-six free-living older volunteers (aged≥65 years).InterventionOlder adults were enrolled and randomly assigned to one of two groups: the camelina group or the placebo group. Subjects consumed daily 35 g of crackers (Camelina enriched crackers or placebo ones) twice daily for 12 weeks.MeasurementsSerum polyunsaturated fatty acid profile, inflammatory status and serum lipid panel parameters were recorded pre and post-intervention.ResultsIn the camelina group, alpha-linolenic acid serum concentration was significantly higher (p<0.01) compared to the placebo group at the end of the study. Concerning inflammatory plasma markers, a significant mean pro-inflammatory interleukin-18 plasma concentration decrease in the placebo group compared to the camelina one was observed (p<0.05). No significant differences in other mean inflammatory markers concentrations post-intervention were noted in either group. Lastly, examining the change in lipid profile, it is noteworthy that a higher reduction of total cholesterol, low-density lipoprotein and triglycerides in the camelina group postintervention, despite the lack of statistical significance.ConclusionCamelina oil significantly elevated the serum alpha-linolenic acid concentration with no significant changes in inflammatory markers and lipid profile.

Early pregnancy associated changes in systemic lipid profiles of mares revealed by high resolution mass spectrometry

Early pregnancy in the mare presents a risk of embryo loss, with little known of the systemic lipid dynamics that contribute to a successful or failed pregnancy. Observations in horses and other species suggest that pregnancy is characterized by an anabolic (i.e. fat deposition) lipid profile initially, followed by a catabolic (lipid mobilization) profile toward the end of gestation. There have been no investigations of lipid metabolism in the very early stages of pregnancy, leading up to and during the time of maternal recognition. High resolution lipidomics presents an unprecedented opportunity to map the changes in lipid profiles of pregnant mares, to examine metabolic pathways contributing to establishment of pregnancy and to identify biomarkers for detection and monitoring of early pregnancy and pregnancy loss. Blood samples were collected from Thoroughbred mares in a commercial breeding operation at day 7 and day 14 following ovulation. Mares were live-covered, and pregnancy tested by transrectal ultrasound at day 14, hereby designated pregnant or non-pregnant. High resolution lipidomics analysis was performed on isolated plasma to compare profiles of pregnant (7P, 14P) and non-pregnant (7NP, 14NP) mares at day 7 and day 14 (total n = 72, split evenly in groups). Lipids were extracted using ice-cold butanol/methanol (1:1 v/v) with 10 mM ammonium acetate containing internal standards.LC separation was performed on a Phenomenex Kinetex C18 Column (2.6 µm, 100 Å, 100 × 2.1 mm) using 5 µL injection volume. The samples were analyzed in data dependent mode using Zeno EAD IDA on the ZenoTOF 7600 system. All data were analyzed using MS-DIAL 5.1. The analysis yielded a total of 10034 unique lipid species across all samples. A total of 277 and 1722 lipids were significantly altered (p<0.05) in pregnant vs non-pregnant animals at day 7 and day 14, respectively. Phosphatidylcholines (PC) were significantly increased in 7P vs 7NP, and phosphatidylethanolamines (PE) were significantly decreased in 7P vs 7NP, with similar trends observed at day 14. Lysophosphatidylcholines (LPC) were increased in 14P vs 14NP. PC and LPC concentrations also increased from day 7 to day 14, but only in pregnant animals. Collectively, these observations point to a major role for phospholipid metabolism in early pregnancy and are consistent with PE being a substrate for methylation to PC, which is a key source of choline crucial for early embryonic development. The roles of PC biosynthesis and supplementation in early equine pregnancy warrant further investigation. Furthermore, alterations in the lipid profile of mares at day 7 post-ovulation challenge the current paradigm that no systemic changes occur in the pregnant mare prior to classical maternal recognition and luteal maintenance.

Vitamin C and E supplementation and high intensity interval training induced changes in lipid profile and haematological variables of young males.

High intensity interval training (HIIT) causes oxidative stress and haematological alteration. Present study was aimed to evaluate the effect of 8 weeks' supplementation of vitamin C and E on HIIT induced changes in lipid profile parameters and haematological variables. Hundred six male adolescent players were randomly assigned into five age-matched groups, i.e., Control (no exercise+placebo), HIIT (placebo), HIIT​+​vitamin-C (1 000​mg/day), HIIT​+​vitamin-E 400 IU/day) and combined HIIT​+​vitamin C and E. Morning and evening sessions (90​min) of HIIT included 4 phases (15​min each) with 3 sets (4​min each). Each 4​min HIIT set consisted of 2​min intense sprint workout (90%-95% of heart rate maximum [HRmax]) followed by 1​min active recovery (60%-70% HRmax) followed by 1​min of complete rest (1:1 work-rest ratio). Lipid profile parameters, haematological variables, endurance capacity and vertical jump were evaluated by standard protocols. Significant decrease in body weight, fat%, total cholesterol, triglyceride, Total Cholesterol/High Density Lipoprotein-Cholesterol and significant increase in High Density Lipoprotein-Cholesterol, maximal oxygen consumption, vertical jump were observed for all four intervention groups. White blood cell count, red blood cell count, haemoglobin percentage and haematocrit values were significantly decreased while platelet count and platelet-to-leukocyte ratio (PLR) ratio were increased significantly only for HIIT group. Blood level of tocopherol and ascorbic acid was significantly increased (values were within the normal range) in all the respective vitamin supplemented groups. Supplementation of vitamin C and E secures health protection with suppressed haemolysis and improved inflammatory blood variables with enhanced explosive leg strength and lipid profile parameters without any concomitant change in endurance capacity.